Glenmark Pharmaceuticals Inc., USA recalls
20 notices naming Glenmark Pharmaceuticals Inc., USA as the recalling firm, since December 11, 2024. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Glenmark Pharmaceuticals Inc., USA: Abiraterone Acetate Tablets USP 500 mg
Hazard (FDA): Labeling: Not Elsewhere Classified
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Azelaic Acid Gel
Hazard (FDA): CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Alyacen 7/7/7
Hazard (FDA): Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Ondansetron Orally Disintegrating Tablets
Hazard (FDA): Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished…
FDAMedicines
Contamination
Glenmark Pharmaceuticals Inc., USA: Nebivolol Tablets
Hazard (FDA): Cross Contamination with Other Products
FDAMedicines
Contamination
Glenmark Pharmaceuticals Inc., USA: Bisoprolol Fumarate and Hydrochlorothiazide Tablets
Hazard (FDA): Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Viorele
Hazard (FDA): Failed Impurities/Degradation Specifications
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Azelaic Acid Gel
Hazard (FDA): CGMP Deviations: Market complaints received for gritty texture (grainy)
FDAMedicines
Dissolution
Glenmark Pharmaceuticals Inc., USA: Theophylline extended-release tablets 400mg
Hazard (FDA): Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results…
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more
Hazard (FDA): CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 2 more
Hazard (FDA): CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Ezetimibe and Simvastatin Tablets
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.
FDAMedicines
Dissolution
Glenmark Pharmaceuticals Inc., USA: Theophylline
Hazard (FDA): OOS results reported for the Dissolution (by UV) test.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle and 3 more
Hazard (FDA): CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Fenofibrate Capsules 67 mg and 38 more
Hazard (FDA): CGMP Deviations
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: chlorproMAZINE Hydrochloride Tablets
Hazard (FDA): CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Atomoxetine Capsules and 13 more
Hazard (FDA): CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more
Hazard (FDA): CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: chlorproMAZINE Hydrochloride Tablets and 1 more
Hazard (FDA): CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
FDAMedicines
Glenmark Pharmaceuticals Inc., USA: Diltiazem Hydrochloride Extended-Release Capsules and 5 more
Hazard (FDA): cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
FDAMedicines